TY - JOUR
T1 - Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection
AU - Shah, Nishi
AU - Dahi, Parastoo B.
AU - Ponce, Doris M.
AU - Sauter, Craig S.
AU - Shaffer, Brian C.
AU - Chung, David J.
AU - Politikos, Ioannis
AU - Lin, Richard J.
AU - Giralt, Sergio A.
AU - Papanicolaou, Genovefa
AU - Ramanathan, Lakshmi V.
AU - Perales, Miguel Angel
AU - Kamboj, Mini
AU - Shah, Gunjan L.
AU - Gyurkocza, Boglarka
N1 - Funding Information:
Financial disclosure: This research was supported in part by National Institutes of Health (NIH) Grant P01 CA23766 and NIH/National Cancer Institute Cancer Center Support Grant P30 CA008748 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
The authors thank Theodore and Laura Hromadka for their generous support. Financial disclosure: This research was supported in part by National Institutes of Health (NIH) Grant P01 CA23766 and NIH/National Cancer Institute Cancer Center Support Grant P30 CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Conflict of interest statement: P.B.D. has served on the advisory board of Kite Pharma. D.M.P. has served on advisory boards for Generon, Kadmon, CareDx, and Ceramedix and as a paid consultant for Guidepoint Global Advisors and the Gerson Lehrman Group. C.S.S. has served as a paid consultant on advisory boards for Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite Pharma, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, and GSK and has received research funds for clinical trials from Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, and Sanofi-Genzyme. B.C.S. has served as a consultant to Hansa Biopharma and Gamida Cell and has received research support from Miltenyi and Celgene. I.P. has served on the Data Safety and Monitoring Board for ExcellThera and has received research funding from Merck. S.A.G. has served as a consultant for Amgen, Actinium, Celgene, Johnson & Johnson, Jazz Pharmaceutical, Takeda, Novartis, Kite Pharma, and Spectrum Pharma and has received research funding from Amgen, Actinium, Celgene, Johnson & Johnson, Miltenyi, and Takeda. M.A.P. has received honoraria from AbbVie, Astellas, Bristol-Myers Squibb, Celgene, Equilium, Incyte, Karyopharm, Kite Pharma, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, Takeda, VectivBio, and Vor Biopharma; has served on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier and on a scientific advisory board for NexImmune; has ownership interests in NexImmune and Omeros; has received research support for clinical trials from Incyte, Kite Pharma, Miltenyi Biotec, and Novartis; and serves in a volunteer capacity as a member of the Board of Directors of the American Society for Transplantation and Cellular Therapy and Be The Match (National Marrow Donor Program), as well as on the CIBMTR Cellular Immunotherapy Data Resource Executive Committee. G.L.S. has received research funding from Amgen and Janssen. B.G. has received research funds for clinical trials from Actinium. The other authors have no conflicts of interest to disclose. Financial disclosure: See Acknowledgments on page 55.e4.
Publisher Copyright:
© 2021 The American Society for Transplantation and Cellular Therapy
PY - 2022/1
Y1 - 2022/1
N2 - There are limited data on outcomes of patients with prior Coronavirus disease 2019 (COVID-19) who proceeded to autologous or allogeneic hematopoietic cell transplantation (HCT). Whether these patients are more susceptible to poor outcomes and recurrence of COVID-19 is unknown. We report a retrospective analysis of outcomes of 15 consecutive patients with hematologic malignancies who experienced COVID-19 and subsequently underwent autologous (n = 8) or allogeneic (n = 7) HCT between June 17, 2020, and February 17, 2021. The cohort included patients with asymptomatic past infections or symptomatic COVID-19 disease. Data were obtained from chart review. Descriptive statistics were used to summarize patient characteristics. Among eight patients who underwent autologous HCT, four had a diagnosis of multiple myeloma and four had a diagnosis of non-Hodgkin's lymphoma. Four of these eight patients did not test positive for anti-SARS-CoV-2 IgG antibody at any point during the course of treatment. The other four patients had detectable anti-SARS-CoV-2 IgG antibodies before undergoing autologous HCT, but only two of these patients remained anti-SARS-CoV-2 IgG antibody-positive at their last follow-up. One patient died from progression of disease. Seven patients with prior COVID-19 underwent allogeneic HCT for acute lymphoblastic leukemia (n = 3), acute myelogenous leukemia (n = 1), chronic myelogenous leukemia in lymphoid blast crisis (n = 1), myelodysplastic syndrome (n = 1), or myelofibrosis (n = 1). Three of the seven patients tested positive for anti-SARS-CoV-2 IgG antibodies following the initial COVID-19 diagnosis; however, only one of these patients retained anti-SARS-CoV-2 IgG antibody following allogeneic HCT. One patient died of infection (fungal and Pneumocystis jirovecii pneumonia) occurring in the context of ongoing treatment for graft-versus-host disease. None of the 15 patients had recurrent COVID-19 infection. Based on our experience, autologous and allogeneic HCT can be safely performed in selected patients with previous COVID-19 infection.
AB - There are limited data on outcomes of patients with prior Coronavirus disease 2019 (COVID-19) who proceeded to autologous or allogeneic hematopoietic cell transplantation (HCT). Whether these patients are more susceptible to poor outcomes and recurrence of COVID-19 is unknown. We report a retrospective analysis of outcomes of 15 consecutive patients with hematologic malignancies who experienced COVID-19 and subsequently underwent autologous (n = 8) or allogeneic (n = 7) HCT between June 17, 2020, and February 17, 2021. The cohort included patients with asymptomatic past infections or symptomatic COVID-19 disease. Data were obtained from chart review. Descriptive statistics were used to summarize patient characteristics. Among eight patients who underwent autologous HCT, four had a diagnosis of multiple myeloma and four had a diagnosis of non-Hodgkin's lymphoma. Four of these eight patients did not test positive for anti-SARS-CoV-2 IgG antibody at any point during the course of treatment. The other four patients had detectable anti-SARS-CoV-2 IgG antibodies before undergoing autologous HCT, but only two of these patients remained anti-SARS-CoV-2 IgG antibody-positive at their last follow-up. One patient died from progression of disease. Seven patients with prior COVID-19 underwent allogeneic HCT for acute lymphoblastic leukemia (n = 3), acute myelogenous leukemia (n = 1), chronic myelogenous leukemia in lymphoid blast crisis (n = 1), myelodysplastic syndrome (n = 1), or myelofibrosis (n = 1). Three of the seven patients tested positive for anti-SARS-CoV-2 IgG antibodies following the initial COVID-19 diagnosis; however, only one of these patients retained anti-SARS-CoV-2 IgG antibody following allogeneic HCT. One patient died of infection (fungal and Pneumocystis jirovecii pneumonia) occurring in the context of ongoing treatment for graft-versus-host disease. None of the 15 patients had recurrent COVID-19 infection. Based on our experience, autologous and allogeneic HCT can be safely performed in selected patients with previous COVID-19 infection.
KW - COVID-19
KW - Hematopoietic cell transplantation
KW - SARS CoV-2
KW - SARS Cov-2 antibody seroconversion
UR - http://www.scopus.com/inward/record.url?scp=85119374174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119374174&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2021.10.004
DO - 10.1016/j.jtct.2021.10.004
M3 - Article
C2 - 34649021
AN - SCOPUS:85119374174
VL - 28
SP - 55.e1-55.e5
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
SN - 2666-6375
IS - 1
ER -